Get the Stockscreener App
0.1546
0.32%
-0.0005
After Hours:
.15
-0.0046
-2.98%
Clearmind Medicine Inc stock is traded at $0.1546, with a volume of 4.14M.
It is down -0.32% in the last 24 hours and down -84.38% over the past month.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
See More
Previous Close:
$0.1551
Open:
$0.1585
24h Volume:
4.14M
Relative Volume:
0.44
Market Cap:
$1.48M
Revenue:
-
Net Income/Loss:
$-6.78M
P/E Ratio:
-0.00362
EPS:
-42.6996
Net Cash Flow:
$-4.67M
1W Performance:
-15.57%
1M Performance:
-84.38%
6M Performance:
-83.91%
1Y Performance:
-87.92%
1-Day Range:
$0.1478
$0.1585
1-Week Range:
$0.1404
$0.2025
52-Week Range:
$0.1404
$2.18
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.1546 | 5.13M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Clearmind Medicine Inc Stock (CMND) Latest News
Clearmind Medicine schedules annual and special shareholder meeting for December - Investing.com
Why Did Clearmind Medicine Shares Jump 7% In Pre-Market Trading? - Benzinga
Tel Aviv Sourasky Medical Center enrolls first patient in Clearmind’s AUD trial - Investing.com Nigeria
Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial - The Manila Times
Clearmind Medicine stock rises after positive safety data in alcohol disorder trial - Investing.com Nigeria
Clearmind reports positive interim safety data for alcohol disorder drug - Investing.com
Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review - The Manila Times
Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of ... - Enidnews.com
Adversity is less terrifying than hope: Clearmind Medicine Inc (CMND) - Setenews
Clearmind Medicine Inc Stock Analysis and ForecastVolatility Index Analysis & Free Trend Following Techniques - earlytimes.in
SciSparc, Clearmind Medicine file Israeli patent application for depression - MSN
Clearmind Medicine initiates Phase I/IIa clinical trial for CMND-100 - MSN
Clearmind Medicine Inc. (CMND) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Clearmind begins phase I/IIa trial for alcohol disorder drug at Hadassah - Investing.com Nigeria
What macro factors could drive Clearmind Medicine Inc. (CWY0) stock higherAnalyst Downgrade & Consistent Profit Trade Alerts - newser.com
Can Clearmind Medicine Inc. (CWY0) stock survive global slowdownSell Signal & High Return Trade Opportunity Guides - newser.com
SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression - The Manila Times
SciSparc: Neurothera Labs Announces Israeli Patent - GlobeNewswire
Clearmind begins phase I/IIa trial for alcohol disorder drug at Hadassah By Investing.com - Investing.com South Africa
Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site - The Manila Times
Clearmind Medicine files Israeli patent for depression treatment - MSN
Will Clearmind Medicine Inc. stock reach all time highs in 2025July 2025 EndofMonth & Real-Time Volume Triggers - newser.com
Clearmind Medicine announces results from Phase I/IIa trial of CMND-100 - MSN
Will Clearmind Medicine Inc. stock keep outperforming rivals2025 Technical Overview & Accurate Intraday Trade Tips - newser.com
Can Clearmind Medicine Inc. (CWY0) stock double in coming yearsMarket Trend Review & Fast Exit Strategy with Risk Control - newser.com
Why Clearmind Medicine Inc. stock could benefit from AI revolutionMarket Growth Review & Weekly Return Optimization Alerts - newser.com
Strategies to average down on Clearmind Medicine Inc.Analyst Upgrade & Breakout Confirmation Alerts - newser.com
How Clearmind Medicine Inc. stock performs after earningsJuly 2025 Closing Moves & Daily Profit Maximizing Trade Tips - newser.com
How sentiment analysis helps forecast Clearmind Medicine Inc.Portfolio Profit Report & Safe Capital Growth Tips - newser.com
Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression - Yahoo Finance
Neurothera Labs and Clearmind Medicine File Patent for Innovative Depression Treatment - TipRanks
Why Clearmind Medicine Inc. (CWY0) stock gets analyst attentionWeekly Market Report & Daily Chart Pattern Signals - newser.com
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):